...
首页> 外文期刊>Cell death & disease. >DZNep inhibits H3K27me3 deposition and delays retinal degeneration in the rd1 mice
【24h】

DZNep inhibits H3K27me3 deposition and delays retinal degeneration in the rd1 mice

机译:DZNep抑制rd1小鼠中的H3K27me3沉积并延迟视网膜变性

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Retinitis pigmentosa (RP) is a group of inherited retinal degenerative diseases causing progressive loss of photoreceptors. Numerous gene mutations are identified to be related with RP, but epigenetic modifications may also be involved in the pathogenesis. Previous studies suggested that both DNA methylation and histone acetylation regulate photoreceptor cell death in RP mouse models. However, the role of histone methylation in RP has never been investigated. In this study, we found that trimethylation of several lysine sites of histone H3, including lysine 27 (H3K27me3), increased in the retinas of rd1 mice. Histone methylation inhibitor DZNep significantly reduced the calpain activity, delayed the photoreceptor loss, and improved ERG response of rd1 retina. RNA-sequencing indicated that DZNep synergistically acts on several molecular pathways that regulate photoreceptor survival in rd1 retina, including PI3K-Akt and photoreceptor differentiation pathways, revealing the therapeutic potential of DZNep for RP treatment. PI3K-Akt pathway and H3K27me3 form a feedback loop in rd1 retina, thus PI3K inhibitor LY294002 reduces phosphorylation of Ezh2 at serine 21 and enhances H3K27me3 deposition, and inhibiting H3K27me3 by DZNep can activate PI3K-Akt pathway by de-repressing gene expression of PI3K subunits Pik3r1 and Pik3r3. These findings suggest that histone methylation, especially H3K27me3 deposition is a novel mechanism and therapeutic target for retinal degenerative diseases, similar to H3K27me3-mediated ataxia-telangiectasia in Atm ?/? mouse.
机译:色素性视网膜炎(RP)是一组遗传性视网膜变性疾病,可导致光感受器逐渐丧失。已鉴定出许多与RP相关的基因突变,但表观遗传修饰也可能与发病有关。先前的研究表明,DNA甲基化和组蛋白乙酰化均调节RP小鼠模型中的感光细胞死亡。但是,从未研究过组蛋白甲基化在RP中的作用。在这项研究中,我们发现组蛋白H3的几个赖氨酸位点,包括赖氨酸27(H3K27me3)的三甲基化在rd1小鼠的视网膜中增加。组蛋白甲基化抑制剂DZNep显着降低了钙蛋白酶活性,延迟了感光细胞的损失,并改善了rd1视网膜的ERG反应。 RNA测序表明,DZNep协同作用于几个调节rd1视网膜光感受器存活的分子途径,包括PI3K-Akt和光感受器分化途径,揭示了DZNep在RP治疗中的治疗潜力。 PI3K-Akt途径和H3K27me3在rd1视网膜中形成反馈环,因此PI3K抑制剂LY294002减少丝氨酸21处Ezh2的磷酸化并增强H3K27me3的沉积,而DZNep抑制H3K27me3可以通过抑制PI3K亚基的基因表达来激活PI3K-Akt途径。 Pik3r1和Pik3r3。这些发现表明,组蛋白甲基化,特别是H3K27me3的沉积是视网膜变性疾病的新机制和治疗靶标,类似于Atmβ/ h中H3K27me3介导的共济失调-毛细血管扩张。老鼠。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号